ANOVA PANCAN result package

Francesco Iorio, EMBL - European Bioinformatics Institute
result parsing started on 2016-03-31 19:01:33
iorio@ebi.ac.uk


Drug Domain: GDSC1000_paper_set, Analysis Domain: panCancer


Individual Feature analysis: MLL2_mut


Feature details and cell panel numbers

Binary feature equal to 1 for samples harboring mutations in MLL2

Number of cell lines positive for this feature: 107


Statistically significant associations identified = 21
association id
FEATURE
Drug id
Propr
Public
Drug Name
Drug Target
N FEATURE pos
N FEATURE neg
log max Conc tested
FEATURE neg logIC50 MEAN
FEATURE pos logIC50 MEAN
FEATURE deltaMEAN IC50
FEATURE IC50 effectSize
FEATURE neg Glass delta
FEATURE pos Glass delta
ANOVA FEATURE pval
Tissue ANOVA pval
MSI ANOVA pval
ANOVA FEATURE FDR %
a64
MLL2_mut
295
1
1
NVP-BHG712
EPHB4
96
823
2.33
3.09
2.17
-0.914
0.56 .
0.56 .
0.52 .
2.39e-06
5.25e-66
4.75e-01
0.6
a139
MLL2_mut
275
1
1
I-BET
BRD2, BRD3, BRD4
96
821
3
3.75
2.87
-0.882
0.51 .
0.52 .
0.47
3.25e-05
2.38e-89
7.65e-01
3.9
a166
MLL2_mut
330
1
1
XMD13-2
RIPK
97
823
2.33
3.44
2.67
-0.774
0.59 .
0.59 .
0.58 .
5.28e-05
3.39e-57
7.47e-01
5.2
a185
MLL2_mut
310
1
1
YM201636
FYV1
96
823
1.63
2.35
1.66
-0.686
0.55 .
0.54 .
0.57 .
6.53e-05
1.52e-36
1.64e-02
5.8
a190
MLL2_mut
257
1
1
NPK76-II-72-1
PLK3
96
823
2.33
2.97
1.92
-1.05
0.62 .
0.62 .
0.6 .
7.25e-05
1.73e-75
3.78e-02
6.3
a194
MLL2_mut
279
1
1
BIX02189
MAP2K5 (MEK5)
96
823
3
4.33
3.74
-0.591
0.49
0.5 .
0.45
7.54e-05
2.66e-71
4.72e-01
6.4
a202
MLL2_mut
287
1
1
KIN001-244
PDPK1 (PDK1)
95
823
3
3.34
2.74
-0.601
0.48
0.49
0.44
8.84e-05
2.26e-42
6.13e-01
7.2
a206
MLL2_mut
260
1
1
NG-25
MAP3K7 (TAK1)
96
823
2.33
2.72
1.9
-0.814
0.48
0.48
0.47
9.17e-05
8.26e-61
9.1e-01
7.3
a209
MLL2_mut
300
1
1
CX-5461
RNA Pol I
96
821
2.33
3.1
2.07
-1.04
0.52 .
0.52 .
0.51 .
9.34e-05
6.38e-45
2.24e-01
7.4
a212
MLL2_mut
305
1
1
TPCA-1
IKK
96
823
3
3.09
2.21
-0.879
0.53 .
0.53 .
0.55 .
9.45e-05
3.6e-62
7.83e-01
7.4
a227
MLL2_mut
226
1
1
GSK1070916
AURKB
92
802
0.94, 2.33
1.74
0.681
-1.06
0.5
0.51 .
0.42
1.21e-04
7.7e-60
3.58e-01
8.8
a232
MLL2_mut
346
1
1
THZ-2-102-1
CDK7
94
809
0.916, 2.996
-1.42
-2.68
-1.26
0.51 .
0.5
0.61 .
1.25e-04
8.7e-38
3.52e-01
8.8
a259
MLL2_mut
333
1
1
T0901317
LXR
96
818
2.33
4.39
3.76
-0.623
0.59 .
0.64 .
0.4
1.66e-04
1.25e-68
1.54e-01
11
a304
MLL2_mut
225
1
1
Genentech Cpd 10
AURKA, AURKB
97
826
2.33
2.58
1.8
-0.782
0.45
0.44
0.5 .
2.52e-04
6.41e-42
3.09e-01
14
a317
MLL2_mut
304
1
1
SB52334
ALK5
96
822
3
4.26
3.9
-0.354
0.28
0.28
0.29
2.82e-04
6.49e-23
5.26e-01
15
a329
MLL2_mut
294
1
1
MPS-1-IN-1
MPS1
96
821
3
3.84
3.17
-0.672
0.49
0.48
0.58 .
2.98e-04
2.78e-42
7.08e-01
15
a350
MLL2_mut
1006
1
1
Cytarabine
DNA synthesis
88
755
0.693
0.263
-0.352
-0.614
0.37
0.37
0.35
3.5e-04
2.49e-16
5.98e-03
16
a457
MLL2_mut
290
1
1
KIN001-260
IKK
96
822
3
4.65
4.07
-0.581
0.49
0.49
0.5 .
5.95e-04
5.85e-85
8.01e-01
21
a469
MLL2_mut
328
1
1
SNX-2112
HSP90
95
816
0.94
-0.461
-1.56
-1.1
0.51 .
0.51 .
0.56 .
6.13e-04
5.66e-43
1.76e-01
22
a494
MLL2_mut
303
1
1
PIK-93
PI4K, PI3K
96
823
3
2.75
1.96
-0.791
0.47
0.47
0.46
7e-04
2.96e-65
2.15e-01
23
a526
MLL2_mut
222
1
1
BX-912
PDPK1 (PDK1)
97
824
2.33
2.83
2.06
-0.768
0.43
0.43
0.43
7.9e-04
5.87e-62
3.74e-01
25


All-tests volcano plot